3D Body Surface Measurement and Display in Radiotherapy Part III: Respiration and Deformation in Post-Surgical Breast Cancer Patients

2006 ◽  
Author(s):  
C.J. Moore ◽  
P.J. Sharrock ◽  
F. Lilley ◽  
D. Burton
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Body Surface ◽  
Surface Measurement ◽  
Breast Cancer Patients

Identification of sentinel lymph node location based on body surface landmarks in early breast cancer patients

Breast Cancer ◽  
2008 ◽  
Vol 16 (3) ◽  
pp. 219-222 ◽  
Author(s):  
Naoko Ueda ◽  
Keiichiro Tada ◽  
Satoshi Miyata ◽  
Mitsuru Koizumi ◽  
Yoshikazu Kuroda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Body Surface ◽  
Breast Cancer Patients ◽  
Node Location

scholarly journals Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
S. A. M. Gernaat ◽  
H. von Stedingk ◽  
M. Hassan ◽  
H. P. Nilsson ◽  
K. A. Rodriguez-Wallberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Linear Regression ◽  
Cancer Patients ◽  
Individual Difference ◽  
Body Surface ◽  
Drug Exposure ◽  
Female Breast Cancer ◽  
Breast Cancer Patients ◽  
Female Breast ◽  
Phosphoramide Mustard

AbstractCyclophosphamide (CPA) dosing by body surface area (BSA, m2) has been questioned as a predictor for individual drug exposure. This study investigated phosphoramide mustard-hemoglobin (PAM-Hb, pmol g−1 Hb) as a biomarker of CPA exposure in 135 female breast cancer patients receiving CPA during three courses based on BSA: 500 mg/m2 (C500 group, n = 67) or 600 mg/m2 (C600 group, n = 68). The inter-individual difference was calculated for both groups by dividing the highest through the lowest PAM-Hb value of each course. The inter-occasion difference was calculated in percentage for each individual by dividing their PAM-Hb value through the group mean per course, and subsequently dividing this ratio of the latter through the previous course. A multivariable linear regression (MLR) was performed to identify factors that explained the variation of PAM-Hb. During the three courses, the inter-individual difference changed from 3.5 to 2.1 and the inter-occasion difference ranged between 13.3% and 11.9% in the C500 group. In the C600 group, the inter-individual difference changed from 2.7 to 2.9 and the inter-occasion difference ranged between 14.1% and 11.7%. The MLR including BSA, age, GFR, and albumin explained 17.1% of the variation of PAM-Hb and was significantly better then the model including only BSA. These factors should be considered when calculating the first dose of CPA for breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document